Edwards Lifesciences Corp [EW] stock is trading at $80.82, up 6.20%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The EW shares have gain 7.34% over the last week, with a monthly amount glided 5.99%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Edwards Lifesciences Corp [NYSE: EW] stock has seen the most recent analyst activity on October 08, 2025, when Oppenheimer downgraded its rating to a Perform. Previously, Evercore ISI upgraded its rating to Outperform on October 07, 2025, and kept the price target unchanged to $88. On July 29, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $100 on the stock. Piper Sandler upgraded its rating to a Overweight but stick to its price target of $80 on April 24, 2025. Stifel upgraded its rating to a Buy and raised its price target to $90 on January 30, 2025. Wolfe Research downgraded its rating to Underperform for this stock on January 16, 2025, but kept the price target unchanged to $60. In a note dated December 16, 2024, BofA Securities upgraded an Buy rating on this stock.
Edwards Lifesciences Corp [EW] stock has fluctuated between $64.89 and $83.00 over the past year. Currently, Wall Street analysts expect the stock to reach $85 within the next 12 months. Edwards Lifesciences Corp [NYSE: EW] shares were valued at $80.82 at the most recent close of the market. An investor can expect a potential return of 5.17% based on the average EW price forecast.
Analyzing the EW fundamentals
Edwards Lifesciences Corp [NYSE:EW] reported sales of 5.69B for the trailing twelve months, which represents a growth of 10.56%. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.29%, and Net Profit Margin reading is 0.73%. To continue investigating profitability, this company’s Return on Assets is posted at 0.31, Equity is 0.41 and Total Capital is 0.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 76.52 points at the first support level, and at 72.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 84.08, and for the 2nd resistance point, it is at 87.34.
Ratios To Look Out For
For context, Edwards Lifesciences Corp’s Current Ratio is 4.68. As well, the Quick Ratio is 3.87, while the Cash Ratio is 2.33. Considering the valuation of this stock, the price to sales ratio is 8.35, the price to book ratio is 4.51 and price to earnings (TTM) ratio is 55.17.
Transactions by insiders
Recent insider trading involved Wood Larry L, Former Affiliate, that happened on Oct 16 ’25 when 8950.0 shares were purchased. CVP, TMTT, Chopra Daveen completed a deal on Aug 25 ’25 to sell 2500.0 shares. Meanwhile, Officer Chopra Daveen bought 2500.0 shares on Aug 25 ’25.
